Late visual outcomes in infants treated with primary bevacizumab for type 1 retinopathy of prematurity

To describe visual acuity findings after 4 years of age in infants treated with primary bevacizumab (IVB) for type 1 retinopathy of prematurity (ROP) and to correlate structural findings on fluorescein angiography (FA) with functional outcomes.

Source: Journal of AAPOS - May 23, 2020 Category: Opthalmology Authors: Sarah Hilkert Rodriguez, Sidney A. Schechet, Michael J. Shapiro, Michael P. Blair Tags: Major Article Source Type: research